CRAD B C-RAD AB

Reminder: C-RAD Web Presentation Year-end Report 2019

Reminder: C-RAD Web Presentation Year-end Report 2019

Presentation of the report for the fiscal year 2019:

Date: Friday January 31, 2020 / kl. 11:00 CET

Venue: Online Presentation

Topic: C-RAD Year-end Report 2019

Procedure:

Please register online through the website:  

After your registration, you will receive a confirmation via email.

A recording of the presentation will be made accessible on the C-RAD website after the presentation.

About C-RAD

C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany and C-RAD (Shanghai) Medical Device Co Ltd in China. Cyrpa International SPRL, a Franco-Belgian laser company, is a wholly owned subsidiary whose operations are integrated. C-RAD AB is listed on NASDAQ Stockholm.

For further information:

Tim Thurn, CEO C-RAD AB, Phone , Email

Attachment

EN
29/01/2020

Underlying

CRAD BC-RAD AB

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on C-RAD AB

Free Trial
CRAD B C-RAD AB

C-Rad AB: 1 director

A director at C-Rad AB bought 8,000 shares at 32.000SEK and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showi...

03/10/23 March 10, 2023 1 EN
Erik Cassel
  • Erik Cassel
GETI B Getinge AB Clas...
PHO PHOTOCURE ASA ... (+37)

Sector Fast Comment - Hospital data update

Better hospital margins in September Weaker procedure volume momentum into Q4 Small positive for capex exposure

GETI B GETINGE AB CLASS B
PHO PHOTOCURE ASA
DEMANT DEMANT A/S
OSSR OSSUR HF.
NOVO B NOVO NORDISK A/S CLASS B
SOBI SWEDISH ORPHAN BIOVITRUM AB
GN GN STORE NORD A/S
ALK B ALK-ABELLO A/S CLASS B
CRAD B C-RAD AB
HNSA HANSA BIOPHARMA AB
EGTX EGETIS THERAPEUTICS AB
VICO VICORE PHARMA HOLDING AB
EKTA B ELEKTA AB CLASS B
COLO B COLOPLAST A/S CLASS B
HUM HUMANA AB
ATT ATTENDO
AZN ASTRAZENECA PLC
ONCO ONCOPEPTIDES AB
BONEX BONESUPPORT HOLDING AB
ARJO B ARJO B
AMBU B AMBU A/S CLASS B
VITR VITROLIFE AB
MCAP MEDCAP
ULTI ULTIMOVACS
BOUL BOULE DIAGNOSTICS AB
IVACC INTERVACC AB
QLINEA Q LINEA AB
OSSD OSSDSIGN
VACC VACCIBODY AS
SYNACT SYNACT PHARMA
ABS ARCTIC BIOSCIENCE
NANEXA NANEXA AB
LINV LINC
IRLAB A IRLAB THERAPEUTICS
FLUO FLUOGUIDE AS
VIMIAN VIMIAN GROUP AB
LUND B H. LUNDBECK A/S
11/09/22 November 9, 2022 1 EN
Erik Cassel
  • Erik Cassel
CRAD B C-RAD AB

C-RAD AB - Resilient despite weaker end markets

Exceptional Q3 sales and EBIT, but orders came in weak We cut ’24e EBIT by 3% on end-market weakness Fair value range of SEK 45-95/share

10/30/22 October 30, 2022 1 EN
Erik Cassel
  • Erik Cassel
GETI B Getinge AB Clas...
PHO PHOTOCURE ASA ... (+10)

Sector Fast Comment - Hospital data update

Better hospital margins in August Congress passed supportive spending bill Small positive for companies with capex exposure

GETI B GETINGE AB CLASS B
PHO PHOTOCURE ASA
CRAD B C-RAD AB
EKTA B ELEKTA AB CLASS B
COLO B COLOPLAST A/S CLASS B
BONEX BONESUPPORT HOLDING AB
ARJO B ARJO B
AMBU B AMBU A/S CLASS B
MCAP MEDCAP
OSSD OSSDSIGN
10/04/22 October 4, 2022 1 EN
Erik Cassel ... (+2)
  • Erik Cassel
  • Jakob Lembke
CRAD B C-RAD AB

C-RAD AB - Record heat on orders beat

Remarkable order intake 35% better than ABGSCe ‘23e EBIT up 8% and ‘24e up 4% Fair value range of SEK 45-95/share

07/21/22 July 21, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch